Goodpath Launches GLP-1 Pricing and Access Model to Help Employers Control Obesity Drug Spend

New updates have been reported about Goodpath.

Goodpath has expanded its Weight Management program with new GLP-1 medication access and pricing options designed to bypass traditional pharmacy benefit manager channels and give employers clearer control over obesity drug costs. The virtual integrative care provider will now offer both direct-to-employer and self-pay GLP-1 pathways, pairing prescribing decisions with behavioral and lifestyle support plus coordinated management of related chronic conditions.

Under the direct-to-employer “GLP-1 Transparent Access” option, Goodpath enables companies to offer clinically managed access to branded GLP-1 drugs at prices it says are at least 35% below PBM list levels, while allowing employers to set their own subsidy and cost-sharing rules. A second self-pay route leverages manufacturer programs such as LillyDirect and NovoCare so that employees can obtain GLP-1 therapies with Goodpath’s clinical oversight without adding drug costs to the employer’s health plan, a structure aimed at benefits leaders and CFOs seeking predictable spend and better visibility into long-term utilization.

Goodpath positions this model as a response to accelerating GLP-1 demand, high list prices, and opaque rebate-driven economics that have left employers with limited visibility into how usage and costs evolve over time. By moving access outside the core pharmacy benefit and integrating GLP-1 prescribing into a broader care model, the company is targeting employers that want to capture the long-term health and productivity benefits of these medications while avoiding open-ended financial exposure.

The Weight Management program treats obesity as a multifactor condition and integrates care for mental health, musculoskeletal pain, sleep disruption, digestive issues, diabetes, and other comorbidities that often undermine weight-loss results if treated in isolation. Goodpath clinicians provide longitudinal, whole-person care, using GLP-1 drugs only when clinically appropriate and aligning treatment plans with each member’s health profile and goals, with the company’s strategy aimed at improving long-term outcomes and reducing total cost of care for employer clients.